Lead Product(s) : MRx-4DP0004
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At the end of treatment period (day 85), 50% of patients receiving MRx-4DP0004 reduced their use of SABA rescue medication as compared to 18.8% for patients receiving placebo.
Product Name : MRx-4DP0004
Product Type : Probiotic
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : MRx-4DP0004
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MRx-4DP0004
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MRx-4DP0004 is an oral, immunomodulatory, single strain live biotherapeutic product, that has been demonstrated to reduce airway inflammation in the treatment of patients with asthma.
Product Name : MRx-4DP0004
Product Type : Probiotic
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : MRx-4DP0004
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efzofitimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : aTyr Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will support process development and scale up of ATYR1923, including the manufacture of bulk drug substance for additional clinical trials in ILD.
Product Name : ATYR1923
Product Type : Protein
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Efzofitimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : aTyr Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Alvelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alvelestat (MPH-966) is a novel, oral small molecule designed to inhibit neutrophil elastase (NE), a neutrophil protease, a key enzyme involved in the destruction of lung tissue.
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Alvelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alvelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1b/2 trial is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of alvelestat in adult patients hospitalized with moderate to severe COVID-19 respiratory disease not yet receiving mechanical ventilation.
Product Name : MPH-966
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Alvelestat
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable